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Background: Limited information is available about clinical outcomes and microbiology of
community-acquired pneumonia in asthma.
Methods: We prospectively studied 4079 CAP patients over a 12-years period and found 139
(3.4%) asthmatic patients.
Results: Asthmatics showed younger age (57  19 vs. 66  19 years), less males (32% vs. 68%)
and less active smokers (15% vs. 25%). Moreover, they had used more frequently inhaled cor-
ticosteroids (ICs, 53% vs. 17%, p < 0.001) and antibiotics (32% vs. 24%, p Z 0.041). Inquired pneumonia; ICs, inhaled corticosteroids; IPD, invasive pneumococcal disease; PSI, pneumonia
lood-urea nitrogen, respiratory rate, blood pressure, age; TBAS, tracheobronchial aspirates; BAL,
f hospital stay; ICU, intensive care unit; PaO2, arterial oxygen tension; FIO2, inspiratory oxygen; SD,
atory volume in 1s; FVC, forced vital capacity; % predicted, % of predicted value; SABA, short-acting
onists;“Severe CAP” presence of at least one major criterion or three minor criteria of the Infectious
Thoracic Society (IDSA/ATS) guidelines; MV, mechanical ventilation; CDC, centre for disease control;
disease.
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1714 S. Terraneo et al.comparison with non asthma-CAP, asthmatics showed at admission more pleuritic pain and dys-
pnoea but less severe pneumonia (PSI, CURB-65, PaO2/FIO2 ratio; p < 0.05). No differences
were observed in CAP microbiology, being Streptococcus pneumoniae the most frequent
isolate. Clinical outcomes in asthmatic patients were similar to the general population (mor-
tality, mechanical ventilation, etc.) but with a shorter median length of stay (6 [3; 9] vs. 7
[4; 10] days, pZ 0.023). The chronic use of ICs did not influence clinical presentation and out-
comes among asthmatic patients.
Conclusions: Asthmatics were younger and showed similar clinical presentation. Consistently
with PSI, asthmatics showed similar outcomes than the general population. The microbial aeti-
ology of CAP in asthma did not differ from the general population and antibiotic therapy should
follow current guidelines.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Asthma is the most common chronic airway inflammatory
disease affecting children and adults with an estimated 300
million involved individuals worldwide [1,2]. In Europe
asthma has a prevalence varying from 2 to >10% and is still
associated with a relevant sanitary and economic burden
despite improved therapeutic options.
The majority of asthmatic patients suffer mild to mod-
erate disease that can be well controlled with standard
therapy [3] allowing clinical stability. However, 5e10% of
asthmatics suffer from a severe disease characterized by
frequent exacerbations and poor clinical control being
often refractory to usual treatment [4,5]. The principal
causes of asthma exacerbations are considered the viral
infections [6e8] possibly accounting for 80% of exacerba-
tions in children and 50% in adults [9] (respiratory syncitial
virus in infancy [10] and rhinovirus in adults [11]). On the
other hand, bacterial infection is usually thought to play a
less significant role in asthma exacerbations [8,12].
Nevertheless, two different studies described that asth-
matic patients also have an increased susceptibility to
bacterial infections and particularly to invasive pneumo-
coccal disease, usually presenting as a pneumonia [13e15],
(IPD). In addition, it has been described that asthma could
be associated with an abnormal innate and/or acquired
immune response to pneumococci [16,17], which makes the
reported association between asthma and increased IPD
biologically plausible [13,14]. Conversely, Lee et al.
described that asthmatics have the same risk of pneumo-
coccal pneumonia as healthy controls [18].
Nonetheless, to date the information available about
epidemiology, clinical presentation and outcomes of CAP in
asthma is poor and no specific recommendations are pro-
vided for these patients in current guidelines [19].
The aim of our study is therefore to determine preva-
lence, clinic characteristics, microbial aetiology and out-
comes of asthmatic patients hospitalized for a CAP and to
assess whether asthmatic patients with CAP do present
different severity and/or microbiological characteristics
and whether current CAP guidelines are fully applicable to
this population or any particular recommendations are
needed.Methods
Patients and definitions
We prospectively studied 4079 consecutive adult patients
hospitalized with CAP between January 2000 and December
2011 in two tertiary care university Hospitals in Barcelona
and Valencia, Spain.
Pneumonia was defined as the presence of a new infil-
trate on the chest radiograph along with signs and symp-
toms suggestive of a lower respiratory tract infection and
no alternative diagnosis during follow-up.
Asthma was defined as the presence of the following
criteria:
- Asthma diagnosis made by a specialist in respiratory or
internal medicine in the medical record
- Characteristics signs and symptoms of asthma in the
patient’ medical history
- Chronic pharmacological treatment specific of asthma
- Spirometric data compatible with the diagnosis of
asthma when available: a variable and generally
reversible airflow obstruction at spirometry (when
available) in accordance with current guidelines for
asthma management (www.ginasthma.org update 2012).
In case the patient did not meet these criteria, he/she
was excluded from the analysis in order to ensure the
strictest selection of asthma patients. This multifactorial
definition was used considering the potential difficulties to
define asthma patients in a prospective database designed
to describe all CAP patients visited in the Hospital and not
specifically asthmatics.
Patients with clinical suspicion of COPD or chronic
bronchitis were also excluded from the asthma group. All
cases of asthma were revised by a second physician expert
in asthma, external to data collection and analysis.
Exclusion criteria from our CAP database included the
following: a) severe immunosuppression, such as in solid-
organ or bone-marrow transplantation or AIDS, or receiving
chemotherapy or other immunosuppressive drugs (>20 mg
prednisone-equivalent per day for 2 weeks); b) hospital-
ization in the preceding 21 days; c) active tuberculosis; d)
CAP in asthma 1715cases with confirmed alternative diagnosis at the end of
follow-up.
Data collection
The following data were recorded on admission to hospital:
age, gender, current smoking, nursing home residency,
comorbid illnesses (respiratory, cardiac, hepatic, renal,
neurological, etc.), and antimicrobial treatment prior to
hospital admission, duration of symptoms prior to visit,
clinical symptoms, physical examination, chest X-rays
pattern, blood analysis and antimicrobial treatment at
admission. PSI and CURB-65 score classes (Online
Supplemental Material), the need of mechanical ventila-
tion (invasive and non-invasive) and ICU, the development
of systemic (septic shock, bacteraemia, acute renal failure,
diarrhoea, etc) or pulmonary (multilobar infiltration, atel-
ectasis, pleural effusion, empyema, respiratory distress)
complications were recorded. “Severe CAP” was defined
when at least one major criterion or three minor criteria of
the Infectious Disease Society of America/American
Thoracic Society (IDSA/ATS) guidelines were present [19].
Follow-up variables were length of hospital stay (LOS) and
30-day mortality. All surviving patients were re-examined
or at least contacted by telephone at 30e40 days after
discharge. Antibiotic therapy and its adequacy to current
Spanish guidelines for CAP treatment [20] were recorded.
Asthma data included asthma treatment: short acting b-
agonists (SABA), long acting b-agonists (LABA), inhaled and
systemic corticosteroids. The most recent lung function
tests before pneumonia were recorded to describe func-
tional status of asthmatic patients.
Due to the observational nature of the study, in the
context of routine clinical and epidemiologic follow-up of
CAP, patients’ written consent was not considered neces-
sary. Hospitals’ Ethical Committees had approved routine
data collection for local CAP cases for epidemiological
reasons and their use for research purposes.
Microbiological evaluation
Routine sampling to determine the microbial aetiology of
pneumonia included sputum, urine for Streptococcus
pneumoniae and Legionella pneumophila antigens, blood
cultures, nasopharyngeal swabs for respiratory viruses.
Pleural puncture, tracheobronchial aspirates (TBAS) and
bronchoalveolar lavage (BAL), when available were
collected for Gram and ZiehleNeelsen stains and for cul-
tures for bacterial, fungal and mycobacterial pathogens.
We only considered valid sputum samples according to
current microbiological standards [21]. Serology tests for
atypical pathogens were performed at admission and after
4e6 weeks (Online Supplemental Material).
Statistical analysis
We show n (%) for categorical variables and median (1st
quartile; 3rd quartile) for continuous variables with non-
normal distribution or mean (SD) for those with normal
distribution. Categorical variables were compared using the
Chi-square test or Fisher’s exact test. Continuous variableswere compared using the Student’s t-test or the nonpara-
metric ManneWhitney U test. Univariate and multivariate
logistic regression analyses were performed to identify
variables predictive of patients with prolonged length of
hospital stay (LOS 6 days) (dependent variable); we also
performed a subgroup analysis for patients with asthma.
Also univariate and multivariate logistic regression analyses
were performed to predict 30-day hospital mortality
(dependent variable). Variables that showed a significant
result univariately (p < 0.1) were included in the corre-
sponding multivariate logistic regression backward stepwise
model (Online Supplemental Material). Variables highly
correlated were excluded from multivariate analyses. The
HosmereLemeshow goodness-of-fit test was performed to
assess the overall fit of the models [22]. The level of sig-
nificance was set at 0.05 (two-tailed). All analyses were




We identified 4079 patients hospitalized with CAP from
January 2000 to December 2011 with a mean  SD age of
64  19 yrs (62% of males). The most frequent co-
morbidities were chronic respiratory diseases (n Z 1519
[37%], of whom COPD: 667 [17%]), chronic heart diseases (n:
733, 18%), neurological diseases (n: 653, 18%) and diabetes
mellitus (n Z 657, 17%). Furthermore, among chronic res-
piratory diseases, asthma was diagnosed in 139 patients
(3.4% of total population). Spirometric data were available
in 64 patients (46%), being the mean FEV172  24[SD]% of
predicted value at manoeuvres before bronchodilator.
Detailed information on asthma treatment was available
in 116 patients (83%): 18 (15%) patients had no inhaled
treatment at time of pneumonia; 26 (22%) were treated
only with SABA on demand; 36 (30%) with a combination
therapy (inhaled corticosteroids and LABA); 36 (30%) only
with inhaled steroids; 6 (5%) asthmatic patients had
received frequent cycles of oral steroids.
Baseline characteristics
Main patients’ characteristics at admission are shown in
Table 1 according to asthma presence. Asthmatics were
more likely to be women, younger and less frequently
current smokers. In addition, they had received more
antibiotic therapy in previous 2 months prior to hospitali-
zation and ICs treatment but no differences were observed
regarding previous treatment with oral steroids.
Pneumonia severity at admission was lower for the
asthma-CAP group that showed a lower PSI (Table 2), less
“severe CAP” [19] cases (asthma-CAP: n Z 19 [15%] vs.
CAP: n Z 756, [23%]; p Z 0.043) and less hypoxaemia in
comparison with the CAP group.
By contrast, asthmatic patients showed at admission a
trend to more expectoration and dyspnoea and had signif-
icantly more pleuritic pain (Table 2). The laboratory data
showed significantly higher leucocytosis but lower creati-
nine levels among asthmatic patients (Table 2).
Table 1 Baseline characteristics of study population according to the diagnosis of asthma.
Variable Asthma-CAP n, (%) 139, (3.4%) CAP n, (%) 3940, (96.6) P value
Demographics
Age (years), mean  SD 57  19 66  19 <0.001
Sex, male/female, n 44/95 2488/1452 <0.001
Smoking, n (%) <0.001
No smoker 97 (70) 1682 (43) <0.001
Current smoking habit 21 (15) 971 (25) 0.010
Former smoking habit 20 (15) 1257 (32) <0.001
Alcohol, n (%) 0.058
No alcohol abuse 120 (86) 3195 (82) 0.23
Current alcohol abuse 19 (14) 529 (14) 0.99
Former alcohol abuse 0 (0) 152 (4) 0.017
Spirometric data, mean ± SDa
FEV1/FVC (%) 67  14 e e
FEV1 (ml) 1.91  0.93 e e
FEV1 (% pred.) 72  24 e e
FVC (ml) 2.8  1.2 e e
FVC (% pred.) 84  20 e e
Previous ICs therapy, n (%) 72 (53) 643 (17) <0.001
Previous oral steroid therapy, n (%)b 1 (1) 71 (2) 0.33
Previous antibiotic therapy, n (%)b 43 (32) 907 (24) 0.041
Previous pneumococcal vaccine, n (%) 11 (10) 459 (16) 0.10
Previous influenza vaccine, n (%) 45 (41) 1255 (43) 0.64
Nursing home, n (%) 0 (0) 91 (3) 0.070
Co-morbidities, n (%)
Diabetes mellitus 16 (12) 641 (17) 0.11
Chronic renal failure 4 (3) 245 (6) 0.10
Chronic heart disorders 17 (12) 716 (18) 0.069
Chronic liver disease 5 (4) 169 (4) 0.68
Neurological disease 13 (10) 640 (18) 0.026
P values less than 0.05 are reported in bold and indicate statistically significant difference. Percentages calculated on non-missing data.
Abbreviations. SD: standard deviation; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; % pred.: % of predicted value;
ICs: inhaled corticosteroid.
a Evaluated at the last clinical control.
b Drugs assumed in last month; for oral steroid use only patients taking less than 20 mg of 20 mg prednisone-equivalent per day were
included in the CAP database.
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Microbiological diagnosis was achieved in 1704 (42%) pa-
tients, 69 asthmatics and 1635 non asthmatics, indicating a
trend to a higher rate of microbiological diagnosis in the
asthma-CAP group (asthma-CAP: 50% vs. CAP: 41%;
p Z 0.056). Distribution of the pathogens did not differ
between groups being S. pneumoniae the most frequent
isolate, followed by respiratory virus and atypical bacteria
in both groups (Table 3).
Overall viral infections, including both monomicrobial
and mixed infections, were found in 18 asthmatics (26%)
and 311 non asthmatic (19%) patients (p Z 0.15). The rate
of bacteraemia did not differ between the 2 groups (10% vs.
8%; pZ 0.42) and were mostly caused by S. pneumoniae in
both groups (Table 4).
Antibiotic treatment
The most frequent initial antimicrobial treatment was a
combination therapy (mostly a betalactam plus macrolide
or quinolone) in both groups (asthma-CAP: n Z 76 [55%];CAP: n Z 2617 [67%]). Within the cases of monotherapy,
fluoroquinolones were the most frequent antibiotics,
particularly among asthmatic patients (asthma-CAP: nZ 57
(41%) vs. CAP: n Z 983 (25%); p < 0.001). The treatment
adequacy according to current Spanish guidelines for CAP
treatment [20] was 96% in asthmatic patient and 92% in non
asthmatic patients (p Z 0.37).Pulmonary and systemic complications
Both pulmonary and systemic complications of CAP are
shown in Table 5. No differences were observed in the
prevalence of CAP complications between asthma-CAP and
CAP groups with the only exception of acute renal failure,
less frequent among asthmatics (asthma-CAP: nZ 16 (11%)
vs. CAP: n Z 887 (23%); p Z 0.001).Main clinical outcomes
Asthmatic patients showed similar rates of 30-day mortality
(4% vs. 7%) and MV (both invasive and non invasive) and a






Physical data at presentation, n (%)
Cough 112 (81) 3083 (79) 0.62
Sputum 87 (64) 2189 (58) 0.11
Sputum purulence 57 (42) 1428 (38) 0.27
Dyspnoea 101 (73) 2537 (66) 0.063
Pleuritic pain 86 (63) 1572 (41) <0.001
Fever 109 (82) 3119 (83) 0.82
Lower level of consciousness 16 (11) 691 (18) 0.061
Vital signs
Respiratory rate, median (1st quartile; 3rd quartile) 24 (20; 28) 24 (20; 30) 0.079
Temperature (C), median (1st quartile; 3rd quartile) 37.4 (36.3; 38.2) 37.6 (36.6; 38.3) 0.15
Temperature <36 C, n (%) 12 (10) 191 (6) 0.043
Systolic blood pressure at presentation (mmHg),
median (1st quartile; 3rd quartile)
123 (110; 143) 130 (115; 150) 0.028
Systolic blood pressure <90 mmHg, n (%) 9 (7) 142 (4) 0.073
Laboratory findings
Creatinine (mg/dL), median (1st quartile; 3rd quartile) 0.9 (0.8; 1.2) 1.0 (0.8; 1.4) <0.001
Creatinine 1.5 mg/dL, n (%) 13 (9) 812 (21) 0.001
C-reactive protein level (mg/dL), median
(1st quartile; 3rd quartile)
15.1 (7.5; 28.8) 17.4 (8.7; 26.8) 0.48
C-reactive protein level 17 mg/dL, n (%) 51 (44) 1651 (51) 0.14
WBC count (x109 cell/L), median
(1st quartile; 3rd quartile)
13900 (10800; 18400) 12400 (9000; 17100) 0.002
Platelets count (x109 cell/L), median
(1st quartile; 3rd quartile)
253 (200; 305.5) 235 (181; 304) 0.054
SatO2 (%),median (1st quartile; 3rd quartile) 94.8 (92.2; 96) 93.5 (90; 95.9) 0.001
PaO2/FIO2, median (1st quartile; 3rd quartile) 304.8 (266.7; 341.7) 282.6 (242.9; 329) 0.007
PSI score classes IeIII, n (%) 93 (74) 1766 (50) <0.001
PSI score classes IVeV, n (%) 32 (26) 1800 (50)
CURB-65 < 3, n (%) 86 (89) 2269 (80) 0.042
CURB-65  3, n (%) 11 (11) 554 (20)
Severe CAP 19 (15) 756 (23) 0.043
Site of care, n (%) 0.084
Outpatients 26 (19) 551 (14) 0.12
Ward 87 (62) 2807 (71) 0.027
ICU admission 26 (19) 580 (15) 0.20
P values less than 0.05 are reported in bold and indicate statistically significant difference. Percentages calculated on non-missing data.
Abbreviations. PaO2: arterial oxygen tension; FIO2: inspiratory oxygen PSI: Pneumonia Severity Index; CURB-65Z confusion, blood-urea
nitrogen, respiratory rate, blood pressure, age; ICU: intensive care unit. “Severe CAP”: presence of at least one major criterion or three
minor criteria according to the Infectious Disease Society of America/American Thoracic Society (IDSA/ATS) guidelines.
CAP in asthma 1717significantly shorter LOS as compared to non asthmatics
(Table 5).
A multivariate analysis was performed to assess factors
associated with prolonged length of hospital stay (LOS 6
days). Risk factors independently associated with pro-
longed LOS were: age65 yrs (odds ratio (OR) 2.6; 95%
confidence interval (95%CI) 2.1e3.2; p < 0.001) previous
alcohol abuse (OR 2.5; 95%CI 1.5e4.4; p Z 0.001), cardiac
failure (OR 1.6; 95%CI 1.2e2.1; p Z 0.001) neurological
disease (OR 1.4; 95%CI 1.1e1.8; p Z 0.012), dyspnoea (OR
1.6; 95%CI 1.3e1.9; p < 0.001), C-RP  17 mg/dL (OR 1.4;
95%CI 1.1e1.7, p Z 0.002), tachypnoea (respiratory rate
30 breaths/min) (OR 1.5; 95%CI 1.2e1.9; p < 0.001),
altered mental status (OR 1.9; 95%CI 1.4e2.5; p < 0.001),
pleural effusion (OR 2.6; 95%CI 1.9e3.5; p < 0.001), mul-
tilobar infiltration (OR: 1.8; 95%CI 1.4e2.3; p < 0.001),bacteraemia (OR 2.2; 95%CI 1.5e3.2; p < 0.001) and ICU
admission (OR 9.6; 95%CI 6.3e14.8; p < 0.001). Asthma was
not associated with prolonged LOS (univariate analysis, OR
0.7; 95%CI 0.5e1.0; p Z 0.085) in the general population.
The model to predict patients with prolonged length of
hospital stay was well calibrated with p-value in Hos-
mereLemeshow test 0.50.
The multivariate analysis for prolonged LOS among asth-
matic patients showed the following risk factors: age 65 yrs
(OR 5.4; 95%CI 2.3e12.7; p < 0.001), multilobar infiltration
(OR 5.3; 95%CI 1.6e17.0; pZ 0.005) and ICU admission (OR
7.3; 95%CI 2.1e25.5; pZ 0.002). The model to predict pro-
longed LOS among asthmatic patients was well calibrated
with p-value in HosmereLemeshow test 0.98.
Finally, the risk factors associated with 30-daymortality in
the multivariate analysis were: age  65 yrs (OR 3.2; 95%CI







Known aetiological diagnosis, n (%) 69 (50) 1635 (41) 0.06
Streptococcus pneumoniae, n (%) 33 (48) 687 (42) 0.34
Respiratory virus, n (%) 11 (16) 228 (14) 0.64
Mixed infections, an (%) 9 (13) 213 (13) >0.99
Atypical bacteria, n (%) 4 (6) 124 (7) 0.58
Mycoplasma pneumoniae, n (%) 3 (4) 59 (4) 0.75
Coxiella burnetii, n (%) 0 (0) 23 (1) 0.32
Chlamydia pneumoniae, n (%) 1 (1) 42 (3) 0.56
Legionella pneumophila, n (%) 2 (3) 117 (7) 0.17
Enterobacteriaceae, n (%)
Klebsiella spp., n (%) 1 (1) 6 (0.4) 0.17
Escherichia coli, n (%) 0 (0) 19 (1) 0.37
Proteus spp., n (%) 0 (0) 1 (0.1) 0.83
Non-fermentating gram-negative bacilli
Pseudomonas aeruginosa, n (%) 1 (1) 42 (3) 0.56
Moraxella catarrhalis, n (%) 0 (0) 6 (0.4) 0.61
Haemophilus influenzae, n (%) 4 (6) 53 (3) 0.25
Staphylococcus aureus, n (%) 1 (4) 42 (3) 0.56
Streptococcus viridans, n (%) 0 (0) 11 (1) 0.49
Data about microorganisms are expressed as n and percentage of positive cultures.
a A mixed infection was described in 13% of both groups being the association of S. pneumoniae and respiratory virus the most
frequent, particularly among asthmatics (asthma-CAP, n Z 6 (9%) vs. CAP, n Z 54 [3%]; p Z 0.017) followed by S. pneumoniae plus
Haemophilus influenzae (asthma-CAP, n Z 0 [0%] vs. CAP, n Z 37 [2%], p Z 0.21), by S. pneumoniae plus Pseudomonas aeruginosa
(asthma-CAP, nZ 0 [0%] vs. CAP, nZ 10 [1%], pZ 0.52) and by S. pneumoniae plus Chlamydia pneumoniae (asthma-CAP, nZ 1 [1%] vs.
CAP, n Z 7 [0.4%], p Z 0.22). The other observed combinations were described in very low percentages each (<0.5%) in both groups.
1718 S. Terraneo et al.1.9e5.4; p < 0.001), neurological disease (OR 2.4; 95%CI
1.7e3.5; p < 0.001), dyspnoea (OR 1.7; 95%CI
1.0e2.7; p Z 0.032), creatinine1.5 mg/dL (OR 2.6; 95%CI
1.8e3.7; p < 0.001), tachypnoea (OR 2.1; 95%CI
1.5e3.0; p< 0.001) PaO2/FIO2< 250 (OR 2.9; 95%CI 2.0e4.1;
p < 0.001), altered mental status (OR 2.6; 95%CI 1.8e3.8;
p< 0.001), ICU admission (OR 2.0; 95%CI 1.3e3.0; pZ 0.001).
By contrast, prolonged LOS (6 days) was a protective factor
for mortality (OR 0.5; 95%CI 0.3e0.7; p < 0.001) while there
was no significant association with asthma. The Hos-
mereLemeshowgoodness-of-fit test indicated that themodel
predictive of 30-day hospital mortality is well calibrated
(pZ 0.19).
In order to investigate the possible influence of ICs in
asthmatic patients we analysed data of clinical presentationTable 4 Aetiology of bacteraemia.
Microorganism Asthma-CAP n, 14
Streptococcus pneumoniae 12 (86)
Staphylococcus aureus 1 (7)
Escherichia coli 1 (7)
Streptococcus viridans 0 (0)
Haemophilus influenzae 0 (0)
Enterococcus 0 (0)
Klebsiella pneumoniae 0 (0)
Proteus mirabilis 0 (0)
Data are number of patients (%).
Abbreviations. CAP: community-acquired pneumonia.and main outcomes by comparing patients chronically
receiving ICswith those not receiving themwithin the asthma-
CAP group and found no significant differences (Table 6).Discussion
The most important findings of our work are:
1. Only 3.4% of our CAP patients had asthma as comorbid-
ity. These patients presented lower age, less smoking
habit and similar data of clinical presentation in com-
parison with non-asthmatics, excepting hypoxaemia
(less frequent) and lower severity indices (PSI, CURB-65,
















Pulmonary complications, n (%)
Empyema 2 (1) 49 (1) 0.85
Pleural effusion 22 (16) 529 (14) 0.47
Multilobar involvement 27 (21) 780 (22) 0.85
Acute respiratory distress 2 (2) 108 (3) 0.35
Systemic complications, n (%)
Bacteraemia 14 (10) 321 (8) 0.42
Development of acute renal failure 16 (11) 887 (23) 0.001
Development of septic shock 4 (3) 209 (5) 0.21
Length of hospital stay, median (1st quartile; 3rd quartile) 6 (3; 9) 7 (4; 10) 0.023
ICU admission, n (%) 26 (19) 580 (15) 0.20
Non invasive mechanical ventilation, n (%) 3 (2) 137 (4) 0.40
Invasive mechanical ventilation, n (%) 3 (2) 155 (4) 0.29
30-day mortality, n (%) 6 (4) 285 (7) 0.19
Percentages calculated on non-missing data.
Abbreviations. SD: standard deviation; ICU: intensive care unit.
CAP in asthma 17192. Clinical outcomes (mortality, MV) were similar for asth-
matics and non asthmatic patients;
3. Previous ICs were not associated with better outcomes
of CAP in asthmatic patients
4. Aetiological agents in asthma-CAP patients were similar
to those of CAP group, being S. pneumoniae always the
most frequently isolate.
To our knowledge this is the first study in the literature
analysing a large CAP series investigating clinical features
and microbial aetiology of pneumonia in asthma. To date,
scarce information has been provided in the literature
about the possible influence of asthma on clinical course of
CAP. In 2010 Bewick et al. [23] described the prevalence ofTable 6 Complications and outcomes of Asthma-CAP according





Severe CAP, n (%)
Systemic complications, n (%)
Bacteraemia
Development of acute renal failure
Development of septic shock
Length of hospital stay, median (1st quartile; 3rd quartile)
ICU admission, n (%)
Non-invasive mechanical ventilation, n (%)
Invasive mechanical ventilation, n (%)
30-day mortality, n (%)
Percentages calculated on non-missing data.
Abbreviations. ICs: inhaled corticosteroids; CAP: community-acquiredpneumococcal serotypes in a cohort of hospitalized CAP
patients in UK and recorded an asthma prevalence of 11.1%.
Our results show only a low percentage of asthmatics
that, in comparison with the general population, were
younger and showed less smoking history. Different factors
could justify this last difference in smoking prevalence, as
the younger age of asthmatic patients or the impact of
smoking on their respiratory symptoms. The younger age of
asthmatic patients should also justify the lower rates of
neurological comorbidities, of mental confusion at admis-
sion and of renal failure.
By contrast, we observed a higher rate of previous
antibiotic treatment in the asthma-CAP group, a finding
that could be justified by the recurrent exacerbationsto ICs therapy.
ICs therapy n,
(%) 72 (51.8%)
Non ICs therapy n,
(%) 67 (48.2%)
P value
0 (0) 2 (3) 0.13
10 (14) 12 (19) 0.47
15 (23) 11 (18) 0.48
0 (0) 1 (2) 0.30
6 (9) 12 (20) 0.10
5 (7) 8 (12) 0.29
8 (11) 7 (11) 0.93
2 (3) 2 (3) >0.99
6 (4; 9) 5 (2; 8) 0.19
10 (14) 15 (23) 0.16
2 (3) 1 (2) >0.99
1 (2) 2 (3) 0.60
1 (1) 3 (5) 0.26
pneumonia; ICU: intensive care unit.
1720 S. Terraneo et al.usually described in asthma. Nevertheless, it is general
belief that viruses are the major causes for asthmatic ex-
acerbations while bacterial infections are less relevant
[12]. Apparently, our results may reveal a physician’s ten-
dency to prescribe frequently antibiotics for asthma exac-
erbations even without a microbiological support to cover
eventual bacterial or mixed infection and to reduce the risk
of severe asthma exacerbation. Nevertheless a panel of
experts do not recommended antibiotic use for asthma
exacerbations in [24] (www.ginasthma.org, update 2012).
Asthmatic patients showed an influenza vaccination rate
similar to the non-asthmatics despite their younger age,
suggesting that the general recommendation to vaccinate
moderate-to-severe asthma patients is possibly applied [1].
On the other side, there was a trend to a lower pneumo-
coccal vaccination rate. Indeed, current international rec-
ommendations do not suggest pneumococcal vaccination
for asthmatics (www.ginasthma.org update 2012) possibly
due to contrasting data [13,14,18]. On the other side CDC
recommends pneumococcal vaccination in asthma since
2010 [25]. In our study it is worth remarking the very low
prevalence of asthma among CAP patients (3.4%) and that
the pneumococcal bacteraemia rates were similar
comparing asthma to non-asthma patients (86% vs. 76%,
Table 4). Conversely, a higher risk of IPD in asthma patients
has been described previously [13,14].
The asthmatic patients of our series presented with
more dyspnoea and pleuritic pain but showed, overall, less
severe pneumonia (PSI, hypoxaemia, etc). The clinical
outcomes of asthmatic patients were in general similar to
those of the CAP group. In fact, asthmatics showed a
significantly shorter (2 days) LOS but equal rates of MV and
mortality (the limited sample size being potentially
responsible for the lack of statistically significance). As a
confirmation, both multivariate analyses for 30-day mor-
tality and prolonged LOS did not show any association
(positive or negative) with asthma. Likely, the potential
excess pneumonia severity that could be expected in
relation to asthma is counterbalanced by younger age and
less co-morbidities of these patients, resulting finally in
similar outcomes. In addition, the characteristic airways
inflammation of asthma, potentially detrimental in CAP,
does not seem to negatively influence CAP outcomes.
Indeed, we could conclude that CAP does not need a special
attention in the asthmatic population, although an excep-
tion could be eventually considered for very severe asthma
where airways remodelling and advanced lung damage
could complicate pneumonia evolution.
Microbiological investigation in our patients showed that
pneumonia in asthma is usually caused by usual CAP path-
ogens (S. pneumoniae, etc.). Therefore, our microbiolog-
ical findings on aetiology of CAP cannot sustain the general
concept of an increased prevalence of viral infections
(although the combination of S. pneumoniae and viruses
was more frequent in asthma patients groups). The clear
microbiological similarities observed between asthma-CAP
and general CAP groups also indicate that empiric treat-
ment of CAP in asthmatics should follow current guidelines
for CAP.
As expected, asthmatics showed a higher rate of previ-
ous ICs therapy being these drugs fundamental to control
asthma. While the risky association between ICs and CAPhas been well demonstrated in COPD [26e28], these data
are not confirmed in asthma [29e31]. Some observational
studies have showed that ICs therapy is not a risk factor for
CAP in asthma [29,30]. On the other hand we cannot
demonstrate a protective effect of ICs in pneumonia com-
plications or outcomes as it has been demonstrated in COPD
patients chronically treated with these drugs [32e34].
These differences have to be explained by substantial dif-
ferences in the host settings and in the innate immunity
between asthma [8] and COPD patients. Our results show
that apparently chronic ICs do not have any influence on
major CAP outcomes in asthma and this is fully consistent
with the prospective study from Yamada et al. supporting
the idea that CAP patho-physiology in asthma is different
than in COPD [35].
The major strength of this work is that, to our knowl-
edge, it is the first large CAP series analysing demographics,
clinical characteristics, microbial aetiology and outcomes
of pneumonia in asthmatic patients.
The possible limitation is that this study was performed
in a single European country (2 centres from Spain) and
could not reflect epidemiology of CAP in asthmatics else-
where. Moreover, due to the nature of our data (database
mainly focused on CAP description and not at asthma
follow-up) it is likely we are underestimating the asthma
prevalence in our population since spirometry was not
available for all our patients and we had to use a multi-
factorial definition of asthma and a second cases’ check by
a pulmonologist expert in asthma in order to exclude all
potential mistakes (COPD etc) and to improve the quality of
our data.
Conclusions
Our study shows low asthma prevalence in a large CAP
population and that clinical outcomes of CAP in asthmatics
are similar to the general population. Furthermore, mi-
crobial aetiology of asthma-CAP did not differ from the
general population. Our data suggest that management of
CAP in asthma should not differ from the general population
and current antibiotic recommendations [19] should be
considered fully valid for this subset of the population.
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